Physician profile
Abhishek Kumar
NPI 1902118706
$4,108.16
in general payments reported to CMS, 2019-2025
21 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $15.42 · 2021: $1,215 · 2022: $104 · 2023: $46.84 · 2024: $290 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $505 · Food and Beverage: $316 · Consulting Fee: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $505.17 |
| Food and Beverage | $315.98 |
| Consulting Fee | $290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,825.44 | 2019-2023 | |
| Intuitive Surgical, INC. | $691.24 | 2021 | |
| Sirtex Medical INC | $538.17 | 2025 | Sir-Spheres Microspheres |
| W. L. Gore & Associates, INC. | $290.00 | 2024 | Product In Development |
| Biocompatibles, INC. | $284.71 | 2019 | |
| United Therapeutics Corporation | $152.30 | 2025 | Remodulin, Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $47.38 | 2019-2023 | |
| Covidien LP | $33.72 | 2019 | |
| Boston Scientific Corporation | $31.99 | 2019 | |
| Pulmonx Corporation | $30.77 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Celgene Corporation | $29.81 | 2019-2020 | |
| Array Biopharma INC | $27.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.65 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.76 | 2019 | |
| Janssen Biotech, INC. | $18.18 | 2025 | Tecvayli, Darzalex, Talvey |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.57 | 2025 | Welireg, Keytruda |
| Janssen Pharmaceuticals, INC | $15.00 | 2019 | |
| Glaxosmithkline, LLC. | $13.50 | 2025 | Jemperli |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2019 | |
| Pfizer INC. | $4.82 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.